Clinical Efficacy of Cellular Immuotherapy Combined with Bortezomib for the Treatment of Patients with Multiple Myeloma

Abstract

To study the clinical efficacy of cellular immunotherapy combined with bortezomib for treatment of patients with multiple myeloma. A total of 76 patients with multiple myeloma in our hospital from October 2012 to October 2013 were selected and randomly divided into 2 groups: the patients in 1 group (38 cases) were treated with cellular immunotherapy combined with chemotherapy including bortezomib (combined therapy group), the patients in other group(38 cases) were treated with only chemotherapy including bortezomib(single chemotherapy as control group). The treatment remission rate, the expression changes of immunophenotype, progression-free survival(PFS) and adverse reactions were compared in the 2 groups. The total remission rate of combined therapy group was significantly higher than that in the control group (P<0.05); the positive rates of CD38+, CD56+ and CD138+ in combined therapy group were all significantly lower than those in control group, and the CD19+ was significantly higher (P<0.05). The PFS rates of 1, 2 and 3 years in the combined therapy group were all significantly higher than those in the control group (P<0.05). The incidence of fatigue, rash, peripheral neuropathy, anemia and granulocyte deficiency in the combined therapy group was all significantly lower than that in the control group (P<0.05). Cellular immunotherapy combined with bortezomib can significantly improve the remission rate, prolong survival, and significantly decrease adverse event rate of multiple myeloma patients.